Martin Holst Lange, research chief and CSO at Danish pharmaceutical company Novo Nordisk, sold 12,000 shares in the company on 4 November.
The shares were sold at a price of 285 Danish kroner per share, a transaction worth 3.42 million Danish kroner.
The transaction was carried out on Nasdaq Copenhagen, according to a disclosure notification.
